74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Haemonetics Corp
Closed
SectorHealthcare
61.86 2.49
Overview
Share price change
24h
Min
60.08
Max
61.97
Income | 3.7M 37M |
|---|---|
Sales | 3M 349M |
P/E Sector Avg | 22.441 57.333 |
EPS | 1.19 |
Profit margin | 10.757 |
Employees | 3,657 |
EBITDA | -37M 59M |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +60.28% upside |
Next Earnings | 8 May 2025 |
|---|
Market Cap | -688M 2.9B |
|---|---|
Previous open | 59.37 |
Previous close | 61.86 |
Technical Score
By Trading Central
Confidence
Bullish Evidence
Haemonetics Corp Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Haemonetics Corp Forecast
Price Target
By TipRanks
60.28% upside
12 Months Forecast
Average 96.71 USD 60.28%
High 115 USD
Low 68 USD
Based on 8 Wall Street analysts offering 12 month price targets forHaemonetics Corp - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Haemonetics Corp
Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE products comprising VASCADE and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen. The company sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.
